New Cancer Drug Boosts Weight, Activity in Patients
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition
ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia.
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drug-maker Pfizer announced Saturday.
ESMO: Pfizer drug helps cancer patients gain weight
Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically meaningful, and Pfizer is now thinking about starting a phase 3 programme for the drug next year.
Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
Experimental drug helps cancer patients regain weight, study shows
Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Medpage Today on MSN1d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
Understanding cancer patients with malnutrition and metabolic dysfunction
Cancer patients frequently experience metabolic dysfunction, leading to severe weight loss correlating with a poor prognosis.
The Pharma Letter3d
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in cancer cachexia
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
Business Wire5d
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer. ii,iii Results will be presented today as a late-breaking ...